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Atualmente, diferentes classes funcionais de peptídeos e toxinas biologicamente ativas isolados 
de diversos organismos são conhecidas. Em medicina, esses polipeptídios podem ser diretamente 
utilizados ou podem servir como modelos para a geração de moléculas derivadas. Aqui, nós 
fazemos referência a três classes de peptídeos e toxinas que agem sobre membranas celulares ou 
sobre sistemas de transporte por membranas: (i) toxinas binárias; (ii) peptídeos antimicrobianos; 
(iii) peptídeos penetradores de células. As toxinas binárias têm sido geneticamente manipuladas 
para gerar imunotoxinas específicas, enquanto os peptídeos antimicrobianos são usados como 
agentes alternativos contra células tumorais e microbianas resistentes. Os peptídeos penetradores 
de células têm aplicações que vão desde a transfecção celular quanto ao transporte intracelular de 
nanopartículas. Nosso grupo vem investigando a capacidade da crotamina, um peptídeo do veneno 
de cascavel, em translocar membranas celulares, bem como de utilizar a crotamina como sistema 
de transporte molecular e de análise de imagens. 
Today, different functional classes of bioactive peptides and toxins isolated from diverse sources 
of living organisms are known. In medicine, these polypeptides present the potential to be used 
structurally unmodified or to serve as templates for molecular design of improved derivatives. 
Here, we refer to members of three classes of remarkable peptides and toxins that act at the cell
membranes level and membrane trafficking systems: (i) the binary toxins (ii) the antimicrobial 
peptides and (iii) the cell penetrating peptides. Binary toxins have been genetically manipulated 
to generate specific immunotoxins, while antimicrobial peptides are in use as alternative agents 
against resistant microbes and tumor cells. Cell penetrating peptides have applications as diverse as 
cell transfection and transport of nanomaterials. Our group is dissecting the capacity of crotamine, 
a peptide from rattlesnake venom, to translocate cell membranes and use it as a delivery system 
in the transducing technology and molecular imaging. 
Keywords: cytolysin, binary toxin, antimicrobial peptide, cell-penetrating peptide, animal 
toxin, nanobiotechnology
1. Binary Bacterial Toxins
A wide variety of bacterial toxins that has the cell 
membrane as a target is presently known. Indeed the 
molecular diversity of bacterial toxins is so remarkable 
that a large number of microorganisms secret several toxic 
peptides and polypeptides devoid of or having catalytic 
activity. All these toxins are capable of intoxicating 
eucaryotic cells by interfering directly with cytoplasmic 
membrane or by using membrane systems to gain access 
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to the interior of cells for the delivery of their active 
domain.
In the first case, single chain proteins or composed of 
two separate water-soluble proteins – which oligomerize 
during their action on phospholipid membrane and form 
pores or channels – encompass the cytolytic toxins of 
bacteria. They are produced by microorganims such as 
Aeromonas hydrophila, Streptococcus pyrogenesis and 
Staphylococcus aureus, as well as by some animals. In 
contrast, toxins produced by strains of enterobacteria 
(Pseudomonas, Shigella, Vibrio cholerae), endospore-
forming bacteria (Clostridium and Bacillus), and even 
plants (Ricinus and Abrus), have a ‘B’ (receptor binding) 
moiety and an ‘A’ (enzymatic active) domain, and constitute 
the binary classes of toxic polypeptides that translocate 
membrane systems. Both groups of membrane-active 
polypeptides – pore-forming and enzymatically active 
binary toxins – will be examined.
The ‘pore-forming toxins, PFTs’ are not true 
translocators, but since they perforate eucaryotic cell 
membrane in multiple points, the internalization of peptide 
molecules through the formed pore sometimes occurs – the 
reason why they are considered here. According to the 
structure of their domains, they use two mechanisms to 
form pores (or channels) in the cell membrane: by insertion 
of amphipathic D-helices or insertion of amphipathic 
E-hairpins which organize in a E-barrel structure. For 
example, the Staphylococcus G-hemolysins (G-toxins), 
that belong to the class of the D-PFTs, when concentrate in 
high densities on cell surface, associate in bundles of 6 to 8 
antiparallel amphipathic D-helices that self insert into the 
membrane and form a hydrophobic channel. On the other 
hand, toxin protein rich in E-sheets, E-PFTs, exemplified 
by Clostridium perfringolysin, Staphylococcus D-toxin, 
streptolysin O, and aerolysin, bind to cell receptors (e.g. 
cholesterol, gangliosides and GPI-anchored proteins), 
oligomerize and one or two E-hairpins of individual 
monomers associate. This association on lipid microdomains 
on cell membranes creates large (250 to 300 Å, with ~30 
monomeric units, e.g. perfringolysin and streptolysin O) or 
small pores (15 to 30 Å, heptameric oligomer, e.g. D-toxin
and aerolysin), that are the result of the insertion of E-barrel 
structures into the lipid bilayer.1 Aerolysin, the preformed 
two-component cytolysin from culture supernatants of 
Aeromonas hydrophila, is constituted by four domains 
(1 to 4) that oligomeryze in a heptameric form on cell 
membrane after activation by endoproteases (trypsin or 
D-chymotrypsin). Domains 1 and 2 recognize the receptor 
(GPI-anchored proteins), which are localized in lipid rafts, 
while domain 3 (and also domain 2) is responsible for 
oligomerization. Domain 4 inserts into the membrane and 
forms the channel or pore. Like other pore forming toxins, 
aerolysin is devoid of enzymatic activity. 
Another interesting bacterial pore-forming toxin 
is streptolysin, secreted by Streptococcus pyrogenesis.
Streptolysin is a cholesterol-dependent cytolysin that 
use cholesterol as receptor in membrane microdomains 
(lipid rafts) for local toxin concentration before pore 
formation. In addition to forming pore, streptolysin can 
translocate a NAD:glycohydrolase into the cytoplasm of 
target eucaryotic cell. This fact makes streptolysin unique 
among the PTFs, since it is a first indication of evolutionary 
adaptation of a pore-forming toxin capable of mediating 
protein transport.1
Bacterial cytolysins formed by two separate hydrophilic 
proteins, which oligomerize during binding to membrane 
microdomains (“lipid raft”), is produced exclusively by 
strains of staphylococcus bacteria. Six toxic protein are 
secreted by Staphylococcus aureus, namely D-hemolysin
(Hla), E-hemolysin (Hlb), J-hemolysin (Hlg), G-hemolysin 
(G-toxin), leukocidin (Luk), and Panto-Valentine leukocidin 
(PVL). Only Hlg, Luk, and PVL are two-component 
and hetero-heptameric pore forming cytolytic toxins.2
Leukocidins are cytolytic to leucocytes, while J-hemolysin 
lyses human erythrocytes. 
Cytotoxic peptides that damage cell membranes by pore 
formation (cytolysin) can also be purified from the toxic 
secretion of animals: melittin is isolated from the venom 
of honeybee, Apis mellifera; ectatomin, from the venom of 
Ectatomina tuberculatum ants; equinatoxin, from the sea 
anemona Actina equina.
Mellitin (APEPEPAPEPEAEADAEADPEAGIGA 
VLKVLTTGLPALISWIKRKRQQG), like G-toxin 
(G-hemolysin), is a peptide constituted of segments of 
alternating residues of polar and apolar aminoacids, 
creating amphipatic D-helix structures that permit the toxin 
to self-associate in solution or in membrane. Amphipatic 
D-helices proved to be the minimal requirements for the 
hemolytic effect of these peptides. At low concentration, 
monomeric peptides are structureless in solution, but 
acquire a D-helical structure in lipid membranes. At high 
concentration, high ionic strenght, or pH, the oligomeric 
D-helical form of peptides is stabilized.3 Melittin is 
cytotoxic to most of eucaryotic cells, but, unlike G-toxin,
mellitin shows antimicrobial activity. The mechanism 
of melittin-induced pore formation is evidenced by the 
membrane thinning effect, conducted by two transitional 
binding states in lipid bilayer: the surface state (S) and the 
pore-forming state (I).4
The ant cytolysin ectatomin is composed by two highly 
homologous amphiphilic polypeptide chains (37 and 
34 amino acid residues) connected by a disulfide bond 
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between Cys22 of A chain and Cys20 of B chain. Each 
chain comprises two anti-parallel D-helices linked by a 
hinge region of four amino acid residues and a disulfide 
bridge (A) Cys12-Cys34 (B) Cys10-Cys32. Ectatomin 
is responsible for the major toxic effect of the venom in 
both mammals and insects. Immunochemical analysis of 
the intracellular distribution of ectatomin showed that the 
toxin gets efficiently inserted into the plasma membrane at 
a concentration of 5 × 10-7 mol L-1 and does not penetrate 
inside the cell.5 Two molecules of ectatomin form each 
pore.
Equinatoxin is another example of cytolysin, but 
produced by cnidarians (sea anemona, Cnidaria). 
Equinatoxin, from Actinia equina, belong to the class of 
actinoporins, the most numerous and most studied cytolisins 
isolated from several genera of the family Actiniidae and 
Stichodactylidae. They comprise 20 kDa basic proteins that 
create pores of 2 nm in eucaryotic and model lipid membranes 
by the self-association of four monomers. Actniporins are 
single chain strucutres dominated by E-sheet, in which 
an amphipathic D-helix, a tryptophan-rich stretch, and a 
RGD-motif are embedded. The flexible N-terminal region 
and a stable beta-sandwich are pre-requisite for proper 
pore (channel) formation by members of the actinoporin 
family.6 In fact, more than 32 species of sea anemones 
have been reported to produce lethal cytolytic peptides 
and proteins. These all cytolysins have been classified into 
four polypeptide groups, based on their primary structures 
and functional properties. Group I consists of 5-8 kDa 
peptides, represented by those from the sea anemones 
Tealia felina and Radianthus macrodactylus. These peptides 
form pores in phosphatidylcholine containing membranes. 
In group II, in addition to equinatoxins, sticholysins and 
magnificalysins produced by Stichodactyla helianthus,
and Heteractis magnifica, respectively, associate typically 
with sphingomyelin containing membranes and create 
cation-selective pores. Group III is formed by lethal 30 to 
40 kDa cytolytic phospholipases A
2
 from Aiptasia pallida
(family Aiptasiidae) and a similar cytolysin, which is devoid 
of enzymatic activity, from Urticina piscivora. A thiol-
activated cytolysin, metridiolysin, with a mass of 80 kDa
from Metridium senile (family Metridiidae) is a single 
representative of the fourth family. Its activity is inhibited 
by cholesterol or phosphatides.7
Thus far, mellitin, equinatoxin and G-toxin are 
prototypes of single chain and single domain cytolysins 
that cause cell lysis by pore fomation after self association 
on lipid membranes, whereas aerolysin and streptolysin are 
representatives of single chain and multi-domain toxins that, 
after binding to a lipid receptor on target cells, oligomerize 
and make a pore or channel on membrane. Streptolysin 
is unique among the pore-forming toxins, since it is the 
first example of bacterial cytolysin able to translocate an 
enzymatic domain. The staphylococcal pore-forming toxins 
J-hemolysin, leukocidin, and Panto-Valentine leukocidin 
are exclusive examples of two separate hydrophilic proteins 
that initially oligomerize, before association and pore 
formation. A detailed figure of these bacterial and animal 
cytolysins can be seen elsewhere. 1,7,8
Differing from preformed or not associated in solution 
two-component (mostly non-enzymatic) cytolysins, which 
cause cell lysis after oligomerization and pore formation, 
there are numerous binary enzymatically active toxins 
secreted by bacteria. These are known as ‘bacterial binary 
toxins’ and they have essentially one catalytic domain or 
chain (‘A’ moiety) and one receptor binding component (‘B’ 
moiety) that is single chain or multimeric. Thus, these toxins 
bind to cell receptor as a preformed ‘A-B’ binary complex 
or as a ‘B’ monomers that is subjected to subsequent 
oligomerization and association of the catalytic ‘A’ protein 
component. Examples of bacterial toxins secreted as 
preformed dimeric or multimeric proteins, with catalytic 
activity, include botulinum neurotoxins A-G (secreted by 
Clostridium botulinum), toxin A and B (from C. difficile),
D-toxin (C. novyi), hemorrhagic and lethal toxins (C. 
sordelli), tetanus neurotoxin (C. tetani), Diphteria toxin 
(Corynebacterium diphteria); exotoxin A (Pseudomonas
aeruginosa), pertussis toxin (Bordetella pertussis), heat-
labile enterotoxin (Escherichia coli), shiga and shiga-like 
toxins (Sighela and other Enterobacteriaceae), and Cholera
toxin (Vibrio cholerae).9 In Figure 1, the tridimensional 
structures of bacterial toxins are presented.
These bacterial binary toxins bind to their respective 
receptor on eucaryotic cell membrane, like the heparin-
binding EGF-like growth factor receptor (diphteria 
toxin), D2-macroglobulin receptor (pertussis exotoxin A), 
glycolipid Gb3 (Shiga toxin), and ganglioside GM1 (Cholera
toxin). Thereafter, the toxin internalization proceeds by 
receptor-mediated endocytosis, in which the proteins 
clathrin or caveolin participate, and by transportation 
from the early endosome to the Golgi apparatus and to 
the endoplasmic reticulum (ER). For instance, diphteria 
and shiga toxins, complexed with their receptors, enter 
cells via plasma membrane-derived vesicles coated with 
the protein clathrin (clathrin-coated surface pits). Cholera
toxin, on the other hand, can alternatively enter into the 
cells by clathrin-independent endocytic pathway, through 
the formation of caveolae-cholesterol dependent structures 
associated to caveolin.10-12 Independent of the endocytic 
carrier for internalization - clathrin or caveolin -, bacterial 
preformed toxins are initially delivered to early endosome, 
and then to the cytosol chiefly by two ways: (i) by making 
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a translocation pore in the membrane or early endosome 
or (ii) by being routed through the Golgi apparatus and to 
endoplasmic reticulum via retrograde transport. In the early 
endosome, diphteria toxin and botulinum neurotoxins, for 
example, are proteolytically cleaved by furin to generate 
heterodimeric forms of toxins that are maintained by S-S 
bonds. Following acidification of endosome, by proton-
pump ATPase, the translocation domains are inserted 
into vesicle membrane, what forms pores and mediates 
the delivery of the catalytic domains into the cytoplasm. 
In case of Cholera toxin, pertussis toxin, and pertussis 
exotoxin A, which contain the C-terminal endoplasmic 
reticulum-retrieval sequence –RDELK, as well as shiga 
toxin and the plant toxin ricin, which surprisingly do not 
have such sequence, the low pH does not influence the 
formation of pore for translocation. These toxins conduct 
the translocation of their active domains from the early 
endosome by using the trans-Golgi network (TGN), and 
then retrogradely to endoplasmic reticulum. Finaly, from 
endoplasmic reticulum into cytoplasm using one pre-
existing translocation machinery in the ER membrane, like 
the Sec61 translocon.10-12
In the cytoplasm, some toxic catalytic domains are 
able to ADP-ribosylate the eucaryotic elongation factor 2 
(eEF2), such as diphteria toxin and Pseudomonas exotoxin 
A, while others, like shiga toxin, possess the enzymatic 
activity of N-glycosidase, removing one adenine residue 
from the 28S ribosomal RNA (rRNA). Both catalytic 
activities culminate with impaired proteins synthesis of 
the intoxicated cells. Enzymatic activities of translocated 
bacterial toxins other than ADP-ribosyl transferase of eEF-2 
and depurination of 28S rRNA include ADP-ribosylation 
of heterotrimeric G-protein (Cholera toxin and pertussis 
toxin), glucosyl transferase of Rho proteins (C. difficile
toxins A and B), and Zn endoproteolysis of vesicular 
docking proteins (clostridial neurotoxins).9,11
Interestingy, several binary toxins, produced by strains 
of genera Clostridium and Bacillus, do not bind to cell 
receptors as a preformed “A-B” protein complex. Toxins 
like Clostridium botulinum C2 toxin (C2), Clostridium 
difficile toxin (CDT), Clostridium perfringens iota toxin 
(L), C. spiroforme toxin (CST), Bacillus anthracis edema 
and lethal toxins, as well as B. cereus vegetative insecticidal 
protein (VIP), initiate cell intoxication first by proteolytic 
activation of a monomer of “B” binding component, 
that occurs in solution or on membrane. Activated “B” 
component interacts with a specific cell membrane receptor 
as a heptamer (preformed in solution) or as monomers that 
subsequently form heptamers on membrane. An enzymatic 
“A” component docks with the cell-bound “B” heptamer, 
and the receptor-holotoxin complex is internalized through 
receptor-mediated endocytosis into early endosomes, 
which become acidified by vacular-type ATPases. An 
acidic environment induces conformational changes in 
Figure 1. Tridimensional structures of membrane translocating binary toxins. Preformed binary toxins: Shigela toxin (pdb 1dmo), Cholera toxin (pdb 1xtc), 
and Ricin, from Ricinus communis (pdb 2aai). In-receptor formed binary toxins: Lethal toxin, from Bacillus anthracis (pdb, 1tzo), and C2 toxin, from 
Clostridium botulinum (pdb 2j42). All E-sheets are represented in light gray, while D-helices are in dark gray. In A it is shown the lateral view of Shigela
toxin (1dmo), with its visible receptor binding domain and catalytic domain, while in B is highlighted the pentameric binding domain. In C and D are 
pictured the same spatial views of Cholera toxins (1xtc) that is shown for Shigela toxin (A, B). In E and F are presented the heptameric prepore structure 
of protective antigen (1tzo) from B. anthracis, in lateral view and a view from the bottom, respectively. In G is shown the tridimensional structure of ricin 
(2aa1), in which the receptor binding domain predominantly composed of E-sheets, and the catalytic domain are clearly distinguished. In H is seen the C2 
toxin transport component (2j42). PDB, written in lowercase, stands for Protein Data Bank of The Research Collaboratory for Structural Bioinformatics 
(RCSB) (http://www.rcsb.org/pdb). 
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the heptameric “B” and its subsequent insertion into the 
endosomal membrane, what allows the translocation 
of “A” component into the cytoplasm.9 C2 toxin, CDT, 
iota toxin, CST and vegetative insecticidal protein (VIP) 
cause ADP-ribosylation of globular acting, which induces 
cytoskeletal disorganization and cell death. Edema toxin is 
responsible for the increasing intracellular levels of cyclic 
AMP (cAMP) that results in edema, while lethal toxin 
causes proteolysis of mitogen-activated protein kinase 
kinases (MAPKK), what disrupts cell signaling and induces 
immunosupression.
Plants also produce toxins that interfere with protein 
synthesis and that are binary preformed proteins. Ricin, a 
protein found in the seeds of Ricinus communis, is one of 
the most studied preformed two-component (heterodimeric) 
plant toxin able to disrupt protein translation. Ricin binds 
to glycoprotein and glycolipids receptors on eucaryotic 
cell membrane that contain a specific residue of galactose 
(via its ‘B’ lectinic receptor binding domain), then it is
internalize by receptor mediated-endocytosis, and its 
catalytic ‘A’ component is translocated to the cytoplasm, 
where it exerts its effect. Similar to the manner of trafficking 
of Cholera and shiga toxins, once ricin-receptor complex 
is endocyted, it is transported into early endosome, 
transferred by vesicular transport to the TNG, then 
retrogradely transported to Golgi complex and, finally, into 
the endoplasmic reticulum. In the endoplasmic reticulum, 
the disulfide bonds connecting ‘A’ and ‘B’ domains are 
reduced and the partial unfold ‘A’ component is translocated 
across the ER membrane via the Sec61p translocon. In 
the cytoplasm, the ricin ‘A’ catalytic domain interact to 
sarcin-ricin domain of large ribosomal subunit RNA (28S 
rRNA) and removes one adenine residue, by cleavage of a 
single N-glycosidic bond, generating a depurinated inactive 
ribosome. In addition to this specific N-glycosidase activity 
on riobosomes, ricin and other ribosome-inactivating 
(RIPs) have a less specific in vitro action on DNA and 
RNA.13,14 Others known ribosome-inactivating proteins are, 
for example, abrin, from the seeds of Abrus precatorius;
gelonin, from Gelonium multiflorum seed; saporin, from 
the soapwort (Saponaria officinalis) seed, leaf and root; 
trichosanthin, from Trichosanthes kirilowii tuber.14 Some 
examples of membrane translocating toxins, their structural 
characteristics and biochemical properties are summarized 
in Table 1. 
In summary, bacterial, and some animal and plant, toxins 
use translocation mechanism based on pore formation on 
cell or vesicular (endosomal) membrane to have access 
to cell cytoplasm, while others relies their intracellular 
trafficking on the pre-existing translocation machinery in 
the ER membrane – a “chaperone” like process. 
Apart from the toxicological health problems associated 
to bacterial intoxication, as well as the medical treatment 
to deal with, themes out of scope in this manuscript, the 
molecular engineering of catalytic and binding domain of 
binary toxins is of particular interest for the specific design 
of derivatives. Thus, chimeras of binary toxins have been 
constructed not only for controlling several malignant 
disorders, but also to serve as vaccine adjuvants and other 
molecular vehicles. For instance, immunotoxins - proteins 
composed of monoclonal antibodies, their fragments or 
specific proteins linked to a plant or bacterial active ‘A’ 
moiety, bind to a surface antigen on a cancer cell, enter 
the cell by endocytosis, delivery the toxin domain, that 
catalytically inhibits a critical cell function, usually protein 
synthesis, and triggers cell death. This elegant and precise 
idea of immunotoxins (‘magic bullets’) was planted by Paul 
Erlich, in the early years of 1900s.
Most effective immunotoxins have been prepared by 
recombinant DNA technology, by fusing pieces of genes 
encoding the toxin domain and the ligand of interest 
(e.g., antibodies and their fragments). To date, the best 
successful examples of use of immunotoxins have been for 
the treatment of hematologic tumors.15,16 Thus, in clinical 
phases of application, recombinant immunotoxins like 
DAB
486
IL2 (fragment 1 to 486 of diphteria toxin - DAB
486
fused to interleukin 2 – IL2), Denileukin diftitox (DAB
389
– IL2), LMB-2 (fragment of Pseudomonas exotoxin A – 
PE38 fused to antibody to the CD25 receptor) and BL22 
(PE38 – anti-CD22), have been used to treat lymphoma and 
leukemia, while Anti-B4-bR (anti-B4 blocked ricin fused 
to anti-CD19), DTGM (fragment 1 to 388 of diphteria 
toxin – DT
388
 fused to human granulocyte-macrophage 
colony stimulating factor, hGM-CSF) are in use against 
non-Hodgkin’s lymphoma, and acute myelogenous 
leukemia, repectively (for more examples, refer to Table 
1, in Pastan et al.16). Clinical trials of immunotoxins for 
treatment of solid tumors are being conducted principally 
with recombinant fragments of ricin or pertussis toxin and 
monoclonal antibodies and their fragments. These hybrid 
immunotoxins target cell surface receptors or antigens 
that are mainly expressed on tumor cell membrane. For 
example, LMB-9 (NCI B3(dsFV)-PE38) recognizes 
Lewis-Y antigen present on the glycoproteins of several 
adenocarcinomas and is used to fight againts breast, 
colon, stomach, and pancreas cancer. SS1P is a hybrid of 
PE38 and anti-mesothelin, that targets tumors that express 
mesothelin, like mesotheliomas, pancreas, ovary, cervix, 
lung, nasopharynx, and oesophagusmesothelin.16,17
Since toxin binding ‘B’ domain facilitate the translocation 
of an active ‘A’ domain, recombinant hybrids can also be 
used to delivery antiviral and antigenic peptides to major 
Membrane-translocating Peptides and Toxins: from Nature to Bedside J. Braz. Chem. Soc.216
histocompatibility complex I (MHC I) molecules and, in 
fact, several toxin B-chain have been tested for specific 
‘vaccination’.18 As additional example of application, 
the protective antigen (PA), the core receptor-binding 
component of Anthrax toxin, which delivers the catalytic 
effector molecules - lethal factor (LF) or edema factor (EF) - 
into the cytosol of mammalian cells, has been used to deliver 
DNA to the cytoplasm. Gaur and co-authors expressed a 
recombinant fusion protein consisting of the PA binding 
domain of the N-terminal 254 amino acids of LF (LF
254
) and 
the DNA-binding domain of the yeast transcription factor 
GAL4 (GAL-DBD), and showed that this fusion protein in 
combination with PA can deliver plasmid DNA containing 
a reporter gene and a GAL4 specific recognition sequence 
into the cytosol of mammalian cells. 
2. Antimicrobial Peptides
It is not only bacterial toxins that utilize pore forming 
and membrane trafficking systems to get into the cytoplasm 
and intoxicate mammalian cells. Animals – from arthropods 
to human – are also equipped with peptides that kill 
microbial cells by disrupting the cytoplasmic membrane 
functions.
Table 1. Some examples of membrane translocating toxins, their structural characteristics and biochemical properties
Source Toxin Structure Receptor on cell 
membrane
Main mechanism 
of membrane 
translocation (*)
Biological activity 
of ‘A’ moiety
Intracelular target
Preformed binary (‘A-B’) toxins
Clostridium
botulinum
Botulinum
neurotoxins
A-B Synaptotagmin II RME, EE Zinc endoprotease VAMP, SNAP-25, 
syntaxin1
C. difficile Toxins A and B A-B Glycans RME, EE Glucosyl transferase Rho proteins
C. tetani Tetanus neurotoxin A-B Neuronal Thy-1 RME/CVE, EE Zinc endoprotease VAMP 
(synaptobrevin)
Corynebacterium
diphteria
Diphteria toxin A-B for HB EGF-like 
GF
RME/CDE, EE ADP-ribosyl
transferase
Elongation factor 2 
(EF-2)
Bordetella pertussis Pertussis toxin  A-(B)
5
Glycoproteins RME,
ER-trafficking
ADP-ribosyl
transferase
HeterotrimericG-
protein
Pseudomonas
aeruginosa
Exotoxin A A-B LRP RME/CDE,
ER-trafficking
ADP-ribosyl
transferase
Elongation factor 2 
(EF-2)
Shigela Shiga toxin  A-(B)
5
Glycolipid Gb3 RME/CCP, 
ER-trafficking
N-glycosylase 28S rRNA
Vibrio cholera Cholera toxin  A-(B)
5
Ganglioside GM1 RME/CCP, 
ER-trafficking
ADP-ribosyl
transferase
HeterotrimericG-
protein
Rinius communis 
(plant)
Ricin A-B B-1,4 linked 
galactosides
RME/CCI,
ER-trafficking
N-glycosylase 28S rRNA
In-receptor or in-solution formed binary (‘A-B’) toxins
Bacillus anthracis Edema toxin EF-(PA)
7
=A-(B)
 7
TEM 8, CMG2 RME, EE Adenylate cyclase cAMP-dependent
proteins
B. anthracis Lethal toxin LF-(PA)
 7 
TEM 8, CMG2 RME, EE Zinc endoprotease MAPKK
B. cereus VIP VIP1-(VIP2)
 7
Unknown RME, EE ADP-ribosyl
transferase
Globular actin
Clostridium
botulinum
C2 toxin C2I –(C2II)
 7
Glycoproteins RME, EE ADP-ribosyl
transferase
Globular actin
C. difficile CDT CDTa-(CDTb)
 7
Unknown RME, EE ADP-ribosyl
transferase
Globular actin
C. perfringens
I toxin Ia-(Ib)
7
Uncharacterized
protein
RME, EE ADP-ribosyl
transferase
Globular actin
*Abbreviations:’A-B’, single chain binary toxin, activated or not by proteolysis; ‘A-(B)
5
’, single chain binary toxin with a pentameric binding domain, 
activated by proteases; ‘A-(B)
7
’, binary tozin with a heptameric binding domain that is oligomerized in receptor or in solution after proteolytic activatiom; 
EF, Edhema factor; LF, lethal factor; PA, protective antigen (EF and LF are‘A’ moities of B. anthacis toxins, while PA is the ’B’ moiety); HB EGF-like 
GF, Heparin-binding EGF-like growth factor; LRP, low-density lipoprotein receptor-related protein; TEM 8, tumor endothelial marker; CMG2, human 
capillary morphogenesis gene 2; RME, receptor-mediated endocytosis; CDE, clathrin-dependent endocytosis; CCP, clatrhin-coated pits; CCI, clathrin- and 
caveolin-independent endocytosis; Caveolin-dependent endocytosis (caveolar endocytosis), EE (Early endosome), route through acidified early endosome; 
ER-trafficking, endoplasmic reiticulum route, through the Golgi apparatus (“retrograde vesicular transport or retrogarde pathway). (*) Some toxins have 
more than one type of mechanism of membrane translocation, like cholera toxin that use clatrhin-independent pathawy, but caveolin-dependent. This table 
was based on reference cited in the text.9-12
Rádis-Baptista et al. 217Vol. 19, No. 2, 2008
Antimicrobial peptides (AMPs) are essential components 
of innate immunity of invertebrates, plants and animals, 
acting as the first line of defense against invading microbes. 
So, to evolve and thrive in an environment dominated by a 
myriad of microorganisms, it was a necessity of all living 
organisms to produce AMPs.
The research about antimicrobial peptides began during 
the late 19th century with the independent works of Ehrlich, 
Metchnikov, Kanthack, and Peterson. In 1879, Ehrlich 
defined the cytoplasmic granules of the granulocytic white 
blood cells and inferred from staining properties that these 
cells carry basic proteins or a mixture of acidic and basic 
ones. In 1883, Metchnikov described, the preeminence 
of phagocytes in antimicrobial host defenses. Kanthack 
and Hardy discovered, in 1895, that phagocytosis of 
bacteria induced granulocytes to degranulate. Afterwards, 
Peterson found antimicrobial activity in aqueous extract 
of pus, and compared the action of basic protein he found 
to protamine from salmon sperm. In 1963, Zeya and 
Spitznagel convincingly showed the existence of cationic 
antimicrobial proline-rich granules in neutrophils of guinea 
pigs, rabbits and humans.20 In the 70’s, the first plant 
antimicrobial peptides, belonging to the group of thionins 
(plant defensins), were isolated.21 Later on, the field of 
AMPs expanded when researchers also independently 
isolated and purified the cecropins, from the pulp of 
silkworm, Bombix mori;22 the magainin, from the skin of 
the amphibian Xenopus;23 and mammalian defensins.24
Excellent reviews cover many aspects of the field of 
gene-enconded, ribosomally synthesized antimicrobial 
peptides.25-31 The molecular diversity of antimicrobial 
peptide is immense and almost a thousand of structures 
have already been characterized. Plenty of information can 
also be retrieved from specialized databases like AMSDb 
(http://www.bbcm.univ.trieste.it/~tossi/amsdb/html) and 
ANTIMIC (http://research.i2r.a-star.edu.sg/Templar/DB/
ANTIMIC/).
Structures of antimicrobial peptides encompass 
molecules ranging in size of 6 to 60 amino acid residues, 
being linear (D-helical and non-helical AMPs), cyclic 
(Rhesus T-defensins, RTDs) or cross-linked by one, two, 
three, or more internal disulfide bridges. Mammalian D-and 
E-defensins and insect defensins constitue the group of 
AMPs structured by three disulfide bonds. In terms of 
amino acid composition and net surface charge, they may 
be rich in one type of amino acid residues (Pro-rich, Pro/
Gly-rich, Trp-rich, His-rich, His/Gly-rich, and Lys- or 
Arg-rich), confering variable indexes of hydrophobicity, 
amphipathicity, net positive charge and, in minor cases, 
net negative charge to these molecules.25,27 Fragments of 
protein domains can also present antimicrobial properties. 
For instance, the carboxyl terminal thirty amino acids of the 
E-subunit of human hemoglobin, which forms a cationic 
D-helix is active against Escherichia coli, Staphylococcus
aureus and Candida albicans.32 Antimicrobial peptides 
are also generated by cleavage of D-casein by strains of 
Lactobacillus acidophilus. Three casein-derived AMPs 
(IKHQGLPQE, VLNENLLR, and SDIPNPIGSENSEK) 
showed antibacterial activity against pathogenic strains of 
Enterobacter sakazakii and Escherichia coli.33
Although AMPs are structurally diverse, they conserve 
the functional ability to interact to and insert into the lipid 
bilayer of microbial cells. The phospholipid membrane 
of microorganism are composed of peptidoglycan 
and lipoteichoic acid (Gram positive bacteria) and 
lipopolysaccharides (LPS, Gram negative bacteria), what 
confer a negatively charged surface by which cationic and 
amphipathic AMPs are electrostatically attracted. One of 
the most immediate killing mechanism, intrinsic to some 
antimicrobial peptides (e.g., magainin, protegrin and 
melittin), is the formation of pore and/or channel in the 
membrane, then causing extensive rupture of membranes, 
by which metabolites leak and cell lysis occur. Three 
models of peptide insertion and membrane permeabilization 
are reported: toroidal pore, carpet and barrel stave (helical-
bundle model). Following attraction, D-helical peptide, 
E-sheet peptides and T-defensins are inserted into the lipid 
bilayer in accord to the peptide/lipid ratio and to one of 
these three models (reviewed in Brodgen34). In the ‘toroidal 
pore model’, D-helices of AMPs, like magainin, protegrin 
and melittin, insert into the membrane and induce lipid 
monolayers to bend continuously through the pore so that 
the water core is lined by both the inserted peptides and the 
lipid head groups. In the ‘carpet model’, AMPs accumulate 
on the lipid bilayer surface, which are orientated in the plane 
of membrane. When high concentration is attained, peptides 
re-orient and AMPs aggregates insert into the membrane 
and disrupt it by producing micelles in a detergent like 
manner. AMPs that act by the ‘carpet model’ are represented 
by cecropin, dermaseptin and again melittin. Finally, in the 
‘barrel-stave model’, antimicrobial peptide D-helices from 
a bundle in the membrane, where the hydrophobic stretches 
of inserted peptides align with the lipid core region of the 
bilayer and the hydrophilic peptide stretches form the pore 
lining. Thus, these three mechanisms contribute to form 
pore, channels and to provoke membrane disruption and 
cell killing.
Although the formation of transmembrane pores 
or channels is the principal mechanism of action of 
antimicrobial peptides, some of their members can 
translocate the cell membrane without causing any 
damage to the lipid bilayer and interfer with intracellular 
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targets. For instance, the antimicrobial peptide buforin 2 
discovered in the stomach tissue of the Asian toad Bufo
bufo gargarizans efficiently crosses lipid bilayers without 
inducing severe membrane permeabilization or lipid flip-
flop.35 Interestingly, the hybrid buforin II-magainin 2, in 
which the proline hinge region of buforin II was fused to the 
amino-terminal helix of magainin 2, is able to translocate 
the bacterial membrane and delivery into the cytoplasm the 
antimicrobial D-helical portion of magainin 2. 
Also, it was demonstrated that the proline-rich 
antimicrobial peptide Bac7(1-35) is rapidly taken up into 3T3 
and U937 cells through a nontoxic energy- and temperature-
dependent process, probably by macropinocytosis and 
direct membrane translocation. Additional, investigations 
also reveal the intracellular uptake of Bac7(1-35) by 3T3 
cells is enhanced during S phase, suggesting a novel 
function for this proline-rich peptide.36 The horseshoe crab 
antimicrobial peptide Polyphemusin I is an amphipathic, 
beta-hairpin connected by a type I’ beta-turn that also has 
membrane translocation activity, in which the beta-sheet 
structure is required for maximum antimicrobial activity 
and for crossing membrane.37 Another antimicrobial peptide 
able to translocate membrane is histatin 5, a 24-residue 
peptide from human saliva with antifungal properties. It 
was demonstrated that histatin 5 translocates across the 
yeast membrane and targets to the mitochondria, indicating 
that the salivary protein histatin 5 exerts its antifungal 
function through a mechanism other than pore formation.38
The small antimicrobial peptide PAF26 (Ac-RKKWFW-
NH(2)), identified by a combinatorial approach, showed 
preferential activity toward filamentous fungi. Thus, the 
short PAF26 is a penetratin-type peptide that has multiple 
detrimental effects on target fungi. Fluorescently labeled 
PAF26 was used to observe the in vivo translocation that 
occurs inside germ tubes and hyphal cells, at concentrations 
as low as 0.3 M (20 times below the minimal inhibitory 
concentration, MIC). In vitro activity analysis of PAF26 
demonstrated its nonspecific binding to RNA. 
From the point of view of clinical application, some 
AMPs are potential candidates for lead drugs not only 
as antimicrobial agents. They exhibit antitumoral and 
mitogenic activities, play roles in signalling transduction 
and adaptative immune response.39 For instance, the 
antimicrobial peptide magainin shows in vitro antitumoral 
activity by triggering apoptosis of human promyelocytic 
leukemia HL-60 cells. The cell death induced by magainin 
occurs via cytochrome c release accompanied by a 
substantial increase of proteasome activity.40 Magainin 
also exerts cytotoxic and antiproliferative activity against 
bladder cancer cells but has no effect on normal murine or 
human fibroblasts.41 One biochemical reason for the action 
of some AMPs as antitumoral is based on the differential 
lipid composition of tumor cells. 
In contrast to the antiproliferative effect of these AMPs, 
mentioned above, the porcine antimicrobial peptide, PR-39, 
alters macrophage viability by inhibiting apoptosis through 
of decreasing the caspase-3 activity, what suggests that this 
antimicrobial peptide might function in the inflammatory 
response not only by killing bacteria, but also by aiding in 
the modulation of the viability of inflammatory cells.42 More 
examples are known, but will not be extensively discussed 
here. Several antimicrobial peptides and their derivatives 
are in distinct phases of clinical trial of application and 
are described elsewhere.30,43 In Table 2, the primary and 
secondary strucures of some antimicrobial peptides, as 
well as their action on membrane and other cell targets, 
are summarized.
3. Cell Penetrating Peptides and Crotamine
Another particular class of membrane-active peptides 
encompasses the cell penetrating peptides (CPPs), formerly 
referred as protein transduction domains (PTDs) or 
membrane transdcution domains (MTPs). Cell penetrating 
peptides are short cationic or amphipathic peptide sequences 
with high affinity for lipid membranes, able to translocate 
membrane systems, and to mediate the intracellular delivery 
of polymeric biomolecules, drugs and nanoparticles.
The first CPPs were recognized in two transcription 
factors: the Tat protein, from HIV-1, and the Antennapedia 
(Antp), from the Drosophila fruit fly.44,45 Later on, short 
peptide fragments of Tat protein (e.g., Tat
47-57
 and Tat
48-60
)
and a segment of 16 amino acids of Antennapedia 
homeodomain (Antp
43-58
, named ‘Penetratin’) were 
demonstrated to be sufficient to translocate through the 
plasma membranes.46,47 Since then, an increasing number 
of natural and synthetic CPPs have been utilized to 
translocate and delivery into the cell cytoplasm and nucleus 
heterologous protein, nucleic acid, drugs, and biomaterials 
with nanometric dimension, both in vitro and in vivo.48-51
Some examples of CPPs are presented in Table 3. 
Due to their physical and chemical characteristics 
(short length, cationic, amphipatic, and structured 
arranged peptides), CPPs are quite similar to AMPs and, 
consequently, share the fundamental property of strong 
interaction with lipid membranes. However, AMPs, as 
above mentioned, predominantly translocate into the cell 
by transient pore formation in the membrane, while CPPs 
enter into the cell by several mechanisms that include all 
types of receptor-mediated endocytosis. Delivery of HIV-
Tat involves caveolae, clathrin-coated pit and vesicles, 
or macropinocytosis, although lipid raft-dependent and 
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Table 2. Examples of antimicrobial peptides, their primary and secondary structures and mode of interaction with lipid membrane
Peptide Amino acid sequences Action on membrane and other targets
A-helical
Buforin 2 TRSSRAGLQFPVGRVHRLLR Translocation     
DNA binding
Cecropin A KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAKamide Pore-forming
Magainin 2 GIGKFLHSAKKFGKAFVGEIMNS Pore-forming
DNA synthesis inhibition
Hybrid cecropin A-
magainin 2 
KAKLFKKIGIGKFLHSAKKFG Membrane disruption
Lower hemolytic activity
Hybrid buforin II-
magainin 2
RAGLQFPVGGIGKFLHSAKKFGK Translocation     
DNA synthesis inhibition
Linear non A-helical
PR-39 RRRPRPPYLPRPRPPPFFPPRLPPRIPPGFPPRFPPRFPamide Translocation     
DNA synthesis inhibition
Histatin DSHAKRHHGYKRKFHEKHHSHRGY Translocation      
Enzyme inhibition
Cross-linked by three disulfide bonds
Human A-defensin VCSCRLVFCRRTELRVGNCLIGGVSFTYCCTRV Membrane permeabilization
DNA synthesis inhibition
Human B-defensin GLGHRSDHYNCVSSGGQCLYSACPIFTKIQGTCYRGKAKCCK Membrane permeabilization 
Plant defensin RTCMIKKEGWGKCLIDTTCAHSCKNRGYIGGNCKGMTRTCYCLVNC Membrane permeabilization
Vesicle aggregation
Circular
Q-defensin RRICRCICGRGICRCICG Bind to glycoproteins on virus surface
Table 3. Sequences of some membrane-translocating/cell penetrating peptides
Peptide Amino acid sequences 
Cationic
HIV1 TAT
47-57
YGRKKRRQRRR
HIV1 TAT
48-60
GRKKKRRQRRRPPQ
Drosophila Ant
43-58
(Penetratin) RQIKIWFQNRRMKWKK
Poli-lisina (R7, sintético) RRRRRRR
PTD-5 (sintético) RRQRRTSKLMKR
Amphipathic
Buforin 2 TRSSRAGLQFPVGRVHRLLR
Transportan (chimera) GWTLNSAGYLLGKINLKALAALAKKIL
Transportan 10 AGYLLGKINLKALAALAKKIL
KALA (sinthetic) WEAKLAKALAKALAKHLAKALAKALKACEA
CL22 KKKKKKGGFLGFWRGENGRKTRSAYERMCNILKGK
Crotamine YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG
Amino acid sequences are represented by one code letter symbols. Positively charged amino acids are shown in boldface and nonpolar amino acid residues 
are underlined. 
clathrin-independent endocytosis seems to be alternative 
mechanisms of cellular uptake.52-56 Indeed, the translocation 
mechanism of CPPs is complex and may involve more 
than one single mode. Whatever the pathway CPPs use 
to translocate membrane (trafficking) systems, it has 
been proved that they can serve to delivery molecules 
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inside the cells and into their internal compartments, like 
endosomes, nucleus, and mitochondria. For instance, 
penetratin (Antp
43-58
) is able to transport into the cell 
short polypeptides (up to 100 residues of amino acid),57
while VP22 (a strucutral polypeptide of Herpes simplex 
vírus type I, HSV-1)58 and HIV-1 Tat
48-60
 can translocate 
larger polypeptides, like the enzymes E-galactosidase and 
thymidine kinase, as well as the protein p53 and other cargos 
of various sizes and physicochemical properties.59-63
CPPs constitute a very reliable alternative to other 
transfections systems. For example, although adenoviral 
vectors can efficiently transduce a broad variety of 
different cell types they can still trigger transient toxic 
effects in animals and patients. Moreover, integrating 
adenoviral vectors carry a greater malignancy risk due 
to their ability to integrate randomly into the target 
genomes.64 In relation to chemical and physical methods 
of transfection, like complexes between DNA and diverse 
polycations (“polyplexes’) or cationic lipids (‘lipoplexes’), 
microinjection, electroporation and particle bombardment 
(‘gene gun’)65, CPPs offer the possibility to deliver genes 
and other biomolecules to specific population of target cells 
with improved efficiency.
In 2004, our group reported a remarkable finding 
in the field of molecular toxinology and of transducing 
technology. By using mouse embryonic stem cells (mES 
cells), we demonstrated that crotamine, a cationic peptide 
from the venom of the South American rattlesnake 
(Crotalus durissus terrificus), selectively translocate into 
actively dividing cells both in vivo and in vitro, in a matter 
of minutes and in a time- and concentration-independent 
fashion.66 Crotamine did not show any toxic effect on mES 
cells in vitro, in micromolar concentrations. By tracking the 
fluorescent derivative of crotamine inside the proliferactive 
cells (AP cells) it was possible to localize the peptide in the 
nucleus. Since crotamine penetrates into cells during G1/S 
period and binding to centrosomes and chromosomes, we 
have proposed the use of crotamine as a marker of centrioles, 
of cell cycle and of actively proliferating (AP) cells. This 
exclusive cell cycle dependent-penetration of crotamine 
indicates that this snake venom peptide is distinct of any 
other known natural CPPs. Additional studies revealed that 
crotamine was also capable of binding electrostatically to 
plasmid DNA, forming DNA-peptide complexes - delivery 
of the plasmid DNA into AP cells, both in vitro and in vivo,
which distinct crotamine from other known natural CPPs 
(Figure 2). Another hallmark was the deciphering of the 
mechanism of crotamine translocation. The mechanism 
of crotamine penetration and cargo delivery involves the 
initial binding to heparan sulfate proteoglycans in the 
uptake, followed by endocytosis and peptide accumulation 
within the acidic endosomal vesicles. Moreover, the 
permeabilization of endosomal membranes induced by 
crotamine results in the leakage of the vesicles contents 
to the cell cytosol.67 The endosomolytic pathway, used by 
crotamine to gain access to the cell cytoplasm is another 
advantage of this natural peptide, that has been explored by 
several research groups for the effective delivery of drugs. 
For instance, a penetrating analog named EB1, is protonated 
in the early-late endosome, forming an amphipathic 
alpha helix that permeabilize the endosomal membrane. 
This endosomolytic mechanism of delivery significantly 
increase the efficiency of short interfering RNA (siRNA) 
uptake and demonstrated that endosomolysis is a necessary 
step toward tranportation of low concentration of active 
compounds for in vivo application.68 Despite of improved 
efficiency of peptide translocation via endosomolytic 
pathway, all type of endocytosis (clathrin-dependent, raft/
caveolin-dependent and macropinocytosis) are implicated 
in the uptake of CPPs, as mentioned above, particularly the 
peptides rich in arginine, which are transported into specific 
intracellular (nuclear) compartments.69
It is worthy of note that crotamine is a highly basic 
toxin, rich in Lys, with an amphipathic character, which 
was originally purified from a venom fraction of Crotalus 
durissus terrificus.70 Crotamine is a low molecular 
weight peptide (4.8 kDa), of 42 amino acid residues 
(YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRW 
KCCKKGSG), cross-linked by three disulfide bonds 
(Cys4–Cys36, Cys11–Cys30 and Cys18–Cys37). Its three-
dimensional structure, as determined by NMR, is arranged 
as apha-beta-beta-beta (DEEE).71-72 Such type of fold is 
found in the classes of human E-defensins (Figure 3) and 
scorpion toxins that target Na+-channels.73 Thus crotamine 
shares the functional properties of cell penetration with 
most CPPs and the structural characteristics with the 
classes of both membrane-active peptides: AMPs and CPPs. 
However, any antimicrobial activity was yet attributed 
to crotamine. Unmodified (naïve) crotamine and their 
potential derivatives are being proposed by us to be used as 
a new gene delivery system, and for other applications like 
nanometric biological tools (nano-biotools) and molecular 
diagnostic of proliferactive cells (tumor cells).
Another interesting natural cell penetration peptide, 
recently characterized, is maurocalcine. Maurocalcine, 
isolated from the venom of the scorpion Scorpio maurus 
maurus, is a 33-amino acid residues peptide toxin 
(GDCLPHLKLCKENKDCCSKKCKRRGTNIEKRCR) 
also cross-linked by three disulfide bridges (Cys3–
Cys17, Cys10–Cys21 and Cys16–Cys32). Its structural 
and functional features make it resembling many cell 
penetrating peptides. Maurocalcine produces Ca2+-release
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Figure 2. In vitro and in vivo nuclear localization of Cy3-crotamine and its association with mitotic chromosomes. (A-D) Internalization of Cy3-crotamine, 
3 h after injection into mice, observed in nuclei (asterisk) and perinuclear space (arrow) of peritoneal liquid cells. (A) Cy3-crotamine. (B) Nuclei stained by 
DAPI (blue). (C) Superimposed images (A) and (B): partial overlapping (pink) of Cy3-crotamine localization (red) and DAPI staining in nuclei (arrow). (D)
Superimposed images (A) and (B), demonstrating overlapping (pink) of Cy3-crotamine localization and DAPI staining within the nuclei, and overlapping 
(yellow) of cytoskeleton immunostained with anti-tubulin antibody (green) and Cy3-crotamine in perinuclear space (A-D = Epifluorescence, EF; bar = 50 
µm). (E-G) Cy3-crotamine strong labeling in nucleus (asterisk) and weak fluorescence in cytoplasm of mouse megakaryocyte (E = Dic, F = Fcm, G = Dic + 
Fcm; bars = 25 µm). (H) Cells pretreated with non-labeled crotamine followed by Cy3-crotamine treatment. Strong fluorescence restricted to the cytoplasm 
indicates saturation of binding sites by non-labeled crotamine in the nucleus (asterisk), as clearly observed in the megakaryocyte (Dic + Fcm; Bar = 10 µm). 
(I-K) Metaphase of lymphoblastic cell. (EF; Magnification, 800×). (I) Cy3- crotamine labeled chromosomes. A banding pattern is produced as shown by the 
chromosome in the inset. (J) DAPI-stained chromosomes. (K) upper position of images (I) and (J): Crotamine labeling (red) is observed on DAPI-stained 
chromosomes. In the inset, the association of crotamine with DAPI-stained chromosomes is depicted (arrow).
Figure 3. Comparison of spatial structures of crotamine and human B-defensin 2. Structures were accessed by means of the structure explorer engine 
from the Protein Data Bank of The Research Collaboratory for Structural Bioinformatics (RCSB) (http://www.rcsb.org/pdb). In one solution structure of 
crotamine, pdb 1h5o, the antiparallel E-sheets were attributed, while in the NMR model ‘pdb 1z99’ they could not be. Both crotamine solution structures 
share the same overall scaffold with human E–defensin 2 (pdb 1e4q). E-sheets are represented in light gray and D-helices are in dark gray.
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from intracellular stores within seconds. It binds directly 
to the skeletal muscle isoform of the ryanodine receptor, an 
intracellular channel target of the endoplasmic reticulum, 
and induces long-lasting channel openings in a mode 
of smaller conductance. Boisseau et al.74 prepared a 
biotinylated derivative of this scorpion peptide (MCab) and 
coupled to a fluorescent streptavidin indicator (Cy3 or Cy5). 
They followed the cell penetration of the entire complex and 
observed the initial interaction with the disialoganglioside 
GD3 – one of the most abundant charged lipid in natural 
membranes. Evidences indicate that maurocalcine may 
cross the plasma membrane directly by cell translocation 
and might carry various drugs and agents of therapeutic 
and diagnostic. 
Taking into consideration that in several cases 
AMPs behave as CPPs, Takeshima and collaborators75
investigated the cellular uptake of fluorescent analogues 
of the two representative natural antimicrobial peptides 
magainin 2 and buforin 2 and compared with the 
representative Arg-rich cell-penetrating HIV1-Tat
47-57
peptide (YGRKKRRQRRR). The dose, time, temperature, 
and energy dependence of translocation suggested that 
the three peptides cross cell membranes through different 
mechanisms. The magainin peptide is internalized within a 
time scale of tens of minutes. The cooperative concentration 
dependence of uptake suggested that the peptide forms a 
pore as an intermediate similar to the observations in model 
membranes. Furthermore, the translocation was coupled 
with cytotoxicity, which was larger for tumor HeLa cells. In 
contrast, the buforin peptide translocates within 10 min by 
a temperature-independent, less concentration-dependent 
passive mechanism without showing any significant 
cytotoxicity at the highest concentration investigated 
(100 Pmol L-1). The buforin peptide, covalently attached 
to the 28-kDa green fluorescent protein, also entered cells, 
also suggesting the potential use of this peptide as a vector 
for macromolecular delivery into cells. 
As pointed out above, several others antimicrobial 
peptide can penetrate the cell and exert their biological 
action. In any case, the comprehension of the mechanism 
of membrane trafficking used by AMPs to get into the cell 
deserves more detailed studies. Therefore, experimental 
methods to evaluate and quantify translocation processes 
mediated by AMPs and CPPs, in vivo and in vitro, with 
or without attached macromolecular cargoes should 
be criteriosly selected.34,76,77 Thus far, the question 
“How different are cell-penetrating peptides and 
antimicrobial peptides?”, intended to be answered by 
several investigators, is still elusive. After all, we may share 
the same point of view of Henriques and collaborators:78
“Potentially, all CPPs are AMPs and all AMPs are CPPs”. 
A clear point is that these peptides (AMPs and CPPs) 
have profoundly diverged, as testified by innumerous 
structures, but still preserving the functional property of 
interacting with membrane and persuading the membrane 
trafficking system. Interestingly, similar point of view 
can be shared concerning to E-PFTs and ‘B’ moiety of 
binary toxins – both are E-hairpins that acquired the 
specilized function of pore-formation.1 While E-PFTs 
perforate cytoplasmic membrane, ‘B’ moiety insert into 
the endosomal membrane after acidification of endosome, 
forming a pore by which ‘A’ moiety is delivered to the 
cytosol.
The increased interest upon CPPs relies on their use as 
target-specific non-invasive delivery technology for drugs, 
heterologous proteins and genes, oligonucleotides and 
nanomaterials The molecular delivery can be addressed 
either to the cytoplasm or to the nucleus of the target 
cells.48-50,77,79 Moreover, potential applications of CPPs 
as delivery systems include different areas of vaccine 
development, cancer immunotherapy, gene delivery, and 
cellular imaging.80-82
4. Concluding Remarks
Although binary toxic proteins (pore-forming and 
membrane-trafficking), antimicrobial peptides and cell 
penetrating peptides are quite dissimilar classes of 
membrane-acting peptide and toxins, they all conserve 
the ability to open a passage through the cell membrane 
or to persuade the membrane trafficking system to exert 
their biological action inside the cell. Pore-forming toxins 
interact first to their receptors that are concentrate in 
microdomains regions on cell membrane (lipid raft), while 
most binary toxins use receptor-mediated endocytosis. 
From this point, toxins perfurate the cytoplasmic 
membrane (cytolysins) or gain access to the cell cytoplasm 
via early endosome. Once in the early endosome, they 
reach the cytoplasm or other intracellular compartment via 
retrograde tranport or endosome sorting. The mechanism 
of pore-formation of antimicrobial peptides has been 
extensively studied and many biophysical aspects are 
known today. On the other hand, translocation of cell-
penetrating peptide is under intensive investigation. Both, 
antimicrobial peptides and cell-penetrating peptides seem 
to interfer with cell membrane in the same way. Most 
antimicrobial peptides form holes in cell membrane, as
cytolysins do, particularly the single chain and single 
domain pore-forming toxin, like melittin. In addition 
to form pores, some antimicrobial peptides are able to 
enter into the cell by receptor-independent endocytosis, 
but this mechanism is restricted for a small number of 
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peptides. In this particular respect, antimicrobial peptides 
and cell-penetrating peptide act in by the same way. 
Cell-penetrating peptides which are natural or synthetic, 
intact or fragments of larger polypeptides share structural 
properties with antimicrobial peptides. Initially, it was 
believed that CPPs might penetrate cell membrane by 
receptor-independent endocytosis, but cummulative 
data has indicated that they also gain access to the cell 
compartments by receptor-mediated endocytosis via 
endosome pathway or retrograde pathway to ER.
Since these classes of peptides and protein toxins have 
structures built by modular domains, in one case (‘A’ and ‘B’ 
domains), or secondarily arranged D-helices and E-sheets,
in other, they can be engineered to convey biomolecules 
and nanoparticles into the cytoplasm of specific cell types, 
as well into the other cell compartments, like the nucleus. 
Therefore, their derivatives are being used for therapeutical 
and diagnostic purposes.
In conclusion, the research horizon of membrane-
translocating peptides and toxins is so wide and bright that 
deserves all of our effort for finding better molecular scapels 
to dissect the cellular processes, as well as to generate 
better delivery system to transport drugs, genes, proteins 
and nanomaterials to specific target cells.
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